"bms" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonHarnessing the Potential of Anti-Cancer Modalities - Bristol Myers Squibb
Harnessing the Potential of Anti-Cancer Modalities Bristol Myers Squibb
Teva fails to overturn patent for BMS’ apixaban in Russian market - The Pharmaletter
Teva fails to overturn patent for BMS’ apixaban in Russian market The Pharmaletter
Revisiting Stock Picks Intel, Progressive, Bristol Myers Squibb - Barron's
Revisiting Stock Picks Intel, Progressive, Bristol Myers Squibb Barron's
BMS expands AI and analytics footprint in India - Insurance Business
BMS expands AI and analytics footprint in India Insurance Business
‘Law & Order’ star Mariska Hargitay teams up with BMS to investigate multiple myeloma research in...
‘Law & Order’ star Mariska Hargitay teams up with BMS to investigate multiple myeloma research in awareness campaign Fierce Pharma
ASCO26: BMS and J&J debut shining multiple myeloma data - Clinical Trials Arena
ASCO26: BMS and J&J debut shining multiple myeloma data Clinical Trials Arena
ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on ...
ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice Fierce Biotech
BMS opens global capability centre in Mumbai - Global Reinsurance
BMS opens global capability centre in Mumbai Global Reinsurance
Diamond-Selling Country Music Superstar Brian Kelley Ready to Ignite Bass Pro Shops Night Race Pr...
Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaig...
Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease Bristol Myers Squibb
BMS taps Anthropic’s Claude for enterprise-wide AI adoption to speed R&D, global workflows - Fier...
BMS taps Anthropic’s Claude for enterprise-wide AI adoption to speed R&D, global workflows Fierce Pharma
ASCO: In next-gen IO race, BioNTech/BMS and Pfizer are divided on overall survival approach - Fie...
ASCO: In next-gen IO race, BioNTech/BMS and Pfizer are divided on overall survival approach Fierce Biotech
Robert Plenge, MD, PhD - Bristol Myers Squibb
Robert Plenge, MD, PhD Bristol Myers Squibb
Edgewise data power rival to BMS and Cytokinetics toward phase 3 - Fierce Biotech
Edgewise data power rival to BMS and Cytokinetics toward phase 3 Fierce Biotech
Survivorship Today: Cancer survivor stories - Bristol Myers Squibb
Survivorship Today: Cancer survivor stories Bristol Myers Squibb
Chris Boerner, Board Chair and Chief Executive Officer - Bristol Myers Squibb
Chris Boerner, Board Chair and Chief Executive Officer Bristol Myers Squibb
The Time Back campaign honoring oncologists in cancer care - Bristol Myers Squibb
The Time Back campaign honoring oncologists in cancer care Bristol Myers Squibb
Cari Gallman - Bristol Myers Squibb
Cari Gallman Bristol Myers Squibb
Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026 - Bristol ...
Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026 Bristol Myers Squibb
Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown - Fierce Biotech
Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown Fierce Biotech
BMS opens Mumbai hub to scale up AI capabilities - theinsurer.com
BMS opens Mumbai hub to scale up AI capabilities theinsurer.com
Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short - BioSpace
Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short BioSpace
BMS and Hengrui Partner on 13 Oncology, Hematology, and Immunology Programs in Deal Worth Potenti...
BMS and Hengrui Partner on 13 Oncology, Hematology, and Immunology Programs in Deal Worth Potentially $15.2 Billion BioPharm International
Addressing disparities and innovation in multiple myeloma - Bristol Myers Squibb
Addressing disparities and innovation in multiple myeloma Bristol Myers Squibb
Takeda’s AI-designed pill bests BMS’ Sotyktu in head-to-head psoriasis trial - BioSpace
Takeda’s AI-designed pill bests BMS’ Sotyktu in head-to-head psoriasis trial BioSpace
Fierce Pharma Asia—BMS-Hengrui's $15B deal; Takeda’s 4.5K layoffs; Daiichi’s oncology ambition - ...
Fierce Pharma Asia—BMS-Hengrui's $15B deal; Takeda’s 4.5K layoffs; Daiichi’s oncology ambition Fierce Pharma
ASCO: BMS’ CELMoD drug doubles PFS in ‘incredibly exciting’ ph. 3 myeloma study - Fierce Biotech
ASCO: BMS’ CELMoD drug doubles PFS in ‘incredibly exciting’ ph. 3 myeloma study Fierce Biotech
3 Reasons to Buy Bristol Myers Squibb Stock - The Motley Fool
3 Reasons to Buy Bristol Myers Squibb Stock The Motley Fool
CRC approval for BMS's Krazati in doubt after confirmatory study miss - FirstWord PHARMA
CRC approval for BMS's Krazati in doubt after confirmatory study miss FirstWord PHARMA
Schneider Electric launches AI-driven continuous BMS monitoring service - Facilities Dive
Schneider Electric launches AI-driven continuous BMS monitoring service Facilities Dive
BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal - BioSpace
BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal BioSpace
BMS 'well prepared' for Camzyos competition as revenue from new products overtakes legacy portfol...
BMS 'well prepared' for Camzyos competition as revenue from new products overtakes legacy portfolio Fierce Pharma
Bristol Myers looks at Houston for potential $1B manufacturing plant - Fierce Pharma
Bristol Myers looks at Houston for potential $1B manufacturing plant Fierce Pharma
BMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaboration - Genetic Engineering an...
BMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaboration Genetic Engineering and Biotechnology News
Bristol Myers Squibb inks $15B biobucks deal to bag Hengrui assets, tap China’s R&D speed - Fierc...
Bristol Myers Squibb inks $15B biobucks deal to bag Hengrui assets, tap China’s R&D speed Fierce Biotech
BMS brings the buzz around late-stage readouts amid a so-so Q1 - Pharmaceutical Technology
BMS brings the buzz around late-stage readouts amid a so-so Q1 Pharmaceutical Technology
Driving global heart health impact through our Corporate Giving program - Bristol Myers Squibb
Driving global heart health impact through our Corporate Giving program Bristol Myers Squibb
BMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3 - Fierce Biotech
BMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3 Fierce Biotech
Bristol Myers Squibb ties science to soccer in World Cup campaign voiced by Ali Krieger - Fierce ...
Bristol Myers Squibb ties science to soccer in World Cup campaign voiced by Ali Krieger Fierce Pharma
Incredible entertainment set for the BMS Fan Zone during Food City 500 weekend - Bristol Motor Sp...
Incredible entertainment set for the BMS Fan Zone during Food City 500 weekend Bristol Motor Speedway
BMS opens Mumbai capability centre - Insurance Asia
BMS opens Mumbai capability centre Insurance Asia
BMS and Hengrui forge $15.2bn alliance for early-stage drugs - Pharmaceutical Technology
BMS and Hengrui forge $15.2bn alliance for early-stage drugs Pharmaceutical Technology
BMS and Oxford BioTherapeutics join forces in TCE discovery pact - Pharmaceutical Technology
BMS and Oxford BioTherapeutics join forces in TCE discovery pact Pharmaceutical Technology
A bold blueprint for transforming outcomes in lupus - Bristol Myers Squibb
A bold blueprint for transforming outcomes in lupus Bristol Myers Squibb
BMS calls time on Zymeworks collab, ending work on phase 1 cancer bispecific - Fierce Biotech
BMS calls time on Zymeworks collab, ending work on phase 1 cancer bispecific Fierce Biotech
BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debut - BioSpace
BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debut BioSpace
Bristol Myers Squibb Announces Dividend - Yahoo Finance
Bristol Myers Squibb Announces Dividend Yahoo Finance
BMS Opens Global Capability Centre in Mumbai - - Insurance Edge
BMS Opens Global Capability Centre in Mumbai - Insurance Edge
BMS and Anthropic collaborate for Claude implementation - Pharmaceutical Technology
BMS and Anthropic collaborate for Claude implementation Pharmaceutical Technology
Bristol Myers and Evinova pen global development partnership - Fierce Biotech
Bristol Myers and Evinova pen global development partnership Fierce Biotech
Honoring oncologists through the Time Back campaign - Bristol Myers Squibb
Honoring oncologists through the Time Back campaign Bristol Myers Squibb
BMS links up with Faro to use AI to improve clinical trial protocols - Fierce Biotech
BMS links up with Faro to use AI to improve clinical trial protocols Fierce Biotech
BMS positions Cobenfy as safer alternative ahead of pivotal Alzheimer’s psychosis readout - BioSpace
BMS positions Cobenfy as safer alternative ahead of pivotal Alzheimer’s psychosis readout BioSpace
Schneider Electric Launches EcoCare for BMS to Deliver Real-Time Operational Intelligence for Mod...
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy...
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) Bristol Myers Squibb
Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi - Bri...
Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi Bristol Myers Squibb
New Hall of Fame class made impact at BMS - Kingsport Times News
New Hall of Fame class made impact at BMS Kingsport Times News
BMS vs. Moderna vs. Pfizer: The RNA Platform Race - Pharmaceutical Executive
BMS vs. Moderna vs. Pfizer: The RNA Platform Race Pharmaceutical Executive
JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff - Clinical Trials Arena
JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff Clinical Trials Arena
Schneider Electric Launches EcoCare for BMS to Support Predictive Building Operations - ARC Advis...
Schneider Electric Launches EcoCare for BMS to Support Predictive Building Operations ARC Advisory Group
Cytokinetics gets jump on BMS as Myqorzo succeeds in non-obstructive HCM trial - FirstWord PHARMA
Cytokinetics gets jump on BMS as Myqorzo succeeds in non-obstructive HCM trial FirstWord PHARMA
Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target - Fierc...
Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target Fierce Biotech
Karen Costello appointed General Manager of Bristol Myers Squibb Benelux - Bristol Myers Squibb
Karen Costello appointed General Manager of Bristol Myers Squibb Benelux Bristol Myers Squibb
Empowering patients with clarity & confidence through UPL program - Bristol Myers Squibb
Empowering patients with clarity & confidence through UPL program Bristol Myers Squibb
BMS, Novartis, Gilead, Iovance dinged over biologics promos in rare spate of CBER untitled letter...
BMS, Novartis, Gilead, Iovance dinged over biologics promos in rare spate of CBER untitled letters Fierce Pharma
BMS and First Horizon Bank partnering to present fifth annual Random Acts of Kindness Tour leadin...
BMS and First Horizon Bank partnering to present fifth annual Random Acts of Kindness Tour leading up to Food City 500 Bristol Motor Speedway
Exclusive | Bristol-Myers Squibb Brings Anthropic’s Claude to 30,000 of Its Staff - WSJ
Exclusive | Bristol-Myers Squibb Brings Anthropic’s Claude to 30,000 of Its Staff WSJ
BMS, J&J factor in HCP education on clot-busting mechanism before milvexian data drop - Fierce Ph...
BMS, J&J factor in HCP education on clot-busting mechanism before milvexian data drop Fierce Pharma
BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments - BioSpace
BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments BioSpace
Strategic pathways for broader CAR T cell therapy access - Bristol Myers Squibb
Strategic pathways for broader CAR T cell therapy access Bristol Myers Squibb
Johnson & Johnson sued by BMS subsidiary in UPC’s first CAR-T patent dispute - IAM Patent
Johnson & Johnson sued by BMS subsidiary in UPC’s first CAR-T patent dispute IAM Patent
Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026 - Business Wire
Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026 Business Wire
OXB expands BMS partnership to churn out lentiviral vectors for commercial CAR-Ts - Fierce Pharma
OXB expands BMS partnership to churn out lentiviral vectors for commercial CAR-Ts Fierce Pharma
BMS is latest Big Pharma firm to partner with China’s Hengrui - C&EN
BMS is latest Big Pharma firm to partner with China’s Hengrui C&EN
Living with idiopathic pulmonary fibrosis: Jean-Michel's journey of strength, advocacy and hope -...
Living with idiopathic pulmonary fibrosis: Jean-Michel's journey of strength, advocacy and hope Bristol Myers Squibb
Sotyktu, take 2: BMS' first-in-class pill gains FDA nod to treat psoriatic arthritis - Fierce Pharma
Sotyktu, take 2: BMS' first-in-class pill gains FDA nod to treat psoriatic arthritis Fierce Pharma
BMS brings 'Emily in Paris' star and cancer survivor Ashley Park aboard campaign honoring oncolog...
BMS brings 'Emily in Paris' star and cancer survivor Ashley Park aboard campaign honoring oncologists Fierce Pharma
BMS Forges $1B+ Antibody Alliance With Chinese Firm Harbour - BioSpace
BMS Forges $1B+ Antibody Alliance With Chinese Firm Harbour BioSpace
Bristol Myers Squibb taps Microsoft's AI detection network for speedy lung cancer diagnosis - Fie...
Bristol Myers Squibb taps Microsoft's AI detection network for speedy lung cancer diagnosis Fierce Biotech
Schizophrenia Care and Evidence-Based Approaches - National Council for Mental Wellbeing
Schizophrenia Care and Evidence-Based Approaches National Council for Mental Wellbeing
"Too many patients in rural America face barriers to cardiovascular care — barriers that - Bristo...
"Too many patients in rural America face barriers to cardiovascular care — barriers that Bristol Myers Squibb
$600m upfront, $15.2bn on the table: Hengrui and BMS forge deal across 13 programs - BioXconomy
$600m upfront, $15.2bn on the table: Hengrui and BMS forge deal across 13 programs BioXconomy
Eliquis price cut drives upbeat guidance for BMS - FirstWord PHARMA
Eliquis price cut drives upbeat guidance for BMS FirstWord PHARMA
Tempus AI And BMS Deepen AI Drug Development Ties As Losses Persist - Yahoo Finance
Tempus AI And BMS Deepen AI Drug Development Ties As Losses Persist Yahoo Finance
'Good Vibes' coming to BMS with Vintage Market Days, March 6-8 - Bristol Motor Speedway
'Good Vibes' coming to BMS with Vintage Market Days, March 6-8 Bristol Motor Speedway
Harbour BioMed docks with BMS in antibody discovery, development deal worth up to $1.1B - Fierce ...
Harbour BioMed docks with BMS in antibody discovery, development deal worth up to $1.1B Fierce Biotech
Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesi...
Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand Strategic Collaboration Pharmaceutical Executive
China’s Hengrui seals US$15.2 billion deal with US pharmaceutical giant BMS - South China Morning...
China’s Hengrui seals US$15.2 billion deal with US pharmaceutical giant BMS South China Morning Post
BMS pens $850M solid tumor pact with T-cell engager biotech Janux - Fierce Biotech
BMS pens $850M solid tumor pact with T-cell engager biotech Janux Fierce Biotech
BMS secures FDA acceptance for Camzyos sNDA - Pharmaceutical Technology
BMS secures FDA acceptance for Camzyos sNDA Pharmaceutical Technology
Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial - Fierce ...
Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial Fierce Biotech
BMS reports positive results in Phase III SCOUT-HCM trial for oHCM - Clinical Trials Arena
BMS reports positive results in Phase III SCOUT-HCM trial for oHCM Clinical Trials Arena
Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling - BioSpace
Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling BioSpace
With declining sales of legacy meds, BMS leans on new growth drivers to weather the storm - Fierc...
With declining sales of legacy meds, BMS leans on new growth drivers to weather the storm Fierce Pharma
BMS says second of its two CELMoDs succeeded in Phase III myeloma study - FirstWord PHARMA
BMS says second of its two CELMoDs succeeded in Phase III myeloma study FirstWord PHARMA
Racing BMS and J&J, Bayer links asundexian to 26% stroke reduction to unblock path to FDA - Fierc...
Racing BMS and J&J, Bayer links asundexian to 26% stroke reduction to unblock path to FDA Fierce Biotech
Assessing Bristol Myers Squibb (BMY) Valuation As Shares Track Mixed Returns And Earnings Outlook...
Assessing Bristol Myers Squibb (BMY) Valuation As Shares Track Mixed Returns And Earnings Outlook Yahoo Finance
FDA Action Alert: BMS, GSK, Aldeyra and More - BioSpace
Bristol Myers Squibb and Gilead Sciences are putting their media accounts into review - Ad Age
Bristol Myers Squibb and Gilead Sciences are putting their media accounts into review Ad Age
Veterans redefining manufacturing leadership in pharma - Bristol Myers Squibb
Veterans redefining manufacturing leadership in pharma Bristol Myers Squibb